Connect with us

Uncategorized

3 Canadian LP Price Target Changes Investors Need To Know

Earnings season has started to heat up for Canadian cannabis producers and we believe that many of these operators need to start putting up real numbers before the market completely loses faith in them. Although there are several industry leaders that are based in Canada, there are a number of companies that are also close […]

The post 3 Canadian LP Price Target Changes Investors Need To Know appeared first on Technical420.

Republished by Plato

Published

on

Earnings season has started to heat up for Canadian cannabis producers and we believe that many of these operators need to start putting up real numbers before the market completely loses faith in them.

Although there are several industry leaders that are based in Canada, there are a number of companies that are also close to being defunct as possible. Going forward, we expect to see a little more choppiness and believe that selectivity will be more important than ever as it relates to Canadian Licensed Producers (LPs).

Today, we wanted to highlight 3 Canadian LPs that recently reported quarterly financial results and believe that these are opportunities to be aware of. These operators have reported impressive basis on a year-over-year basis and want to highlight the responses that broker-dealers have had to the results.

On August 10th, Canopy Growth Corporation (WEED.TO) (CGC) reported first quarter financial results that showed impressive growth and the market responded favorably to the numbers. Several broker-dealers have changed their price targets on Canopy Growth following the quarterly report and have highlighted the changes below:

  1. Canaccord Genuity raised its price target to $22 from $21
  2. CIBC lowered its price target to $25 from $26
  3. Cowen and Company raised its price target to $30 from $27
  4. Cormark raised its price target to $23.50 from $21 (CAD)

After Canopy Growth reported earnings, Tilray Inc. (TLRY) released second quarter financial results and the market seems to be less impressed with the results. After the announcement, several broker-dealers changed their price target on the Canadian cannabis producer and have highlighted the changes below:

  1. Piper Sandler lowered its price target to $15 from $20
  2. Cowen and Company lowered its price target to $8.50 from $9
  3. Stifel lowered its price target to $6 from $6.50

Last week, MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) released second quarter financial results and reported several substantial milestones. Although we are favorable on how the story has transformed into a domestic and international cannabis oil company, the stock is currently trading in a range and we are watching for a breakout. The company did not receive many upgrades or changes from broker-dealers and we have highlighted the changes below:

  1. Canaccord Genuity reiterated its Speculative Buy Rating and its $2.75 (CAD) price target

Pursuant to an agreement between StoneBridge Partners LLC and Medipharm Labs we have been hired for a period of 180 days beginning August 18, 2020 and ending March 18, 2020 to publicly disseminate information about (LABS) including on the Website and other media including Facebook and Twitter. We are being paid $6,000 per month (LABS) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero (0) shares of (LABS), which we purchased in the open market. We plan to sell the “ZERO” shares of (LABS) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (LABS) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share Share - Facebook Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Source: https://technical420.com/cannabis-article/3-canadian-lp-price-target-changes-investors-need-to-know/

Uncategorized

Will BevCanna Be Able To Compete Long Term With The Likes Of HEXO Corp. and Canopy Growth?

After staying quiet for several months, BevCanna Enterprises Inc. (BEV.CN) (BVNNF) has been busy and has reported three separate announcements this week. One of the most important developments to be reported by BevCanna was the completion of trial production runs of its exclusively licensed line of Keef Beverages as well as the white-label beverages it […]

The post Will BevCanna Be Able To Compete Long Term With The Likes Of HEXO Corp. and Canopy Growth? appeared first on Technical420.

Republished by Plato

Published

on

After staying quiet for several months, BevCanna Enterprises Inc. (BEV.CN) (BVNNF) has been busy and has reported three separate announcements this week.

One of the most important developments to be reported by BevCanna was the completion of trial production runs of its exclusively licensed line of Keef Beverages as well as the white-label beverages it is producing for State B Beverages.

BevCanna produced and evaluated multiple formulations (i.e. sparkling water, tea-based and soda formats) and multiple bottling formats. The company conducted tests on shelf stability and we are favorable on the thoroughness of the pre-production process. BevCanna plans to start product commercialization by the first quarter of 2021, assuming that it is granted the necessary processing licenses.

Another key development is related to strengthening BevCanna’s balance sheet. The Canadian cannabis beverage company recently received a $750,000 capital injection from a private placement as well as $500,000 from the exercising of 1.5 million stock options by the senior management team.

The other announcement from BevCanna was related to the addition of retail beverage marketer Donald Wood to the company’s independent advisory board. The company expects him to bring a wealth of sales and marketing experience in the beverage sector to the business and we will monitor the impact that he has on the operation.

Currently, BevCanna is trading at $0.27 and we are favorable on the management teams’ decision to exercise the stock options. We are of the opinion that this shows that the management team has confidence in the operation and considers it to be undervalued.

The funds are being used to prepare BevCanna’s industry-leading high-capacity beverage manufacturing facility for the granting of a standard processing license from Health Canada. Prior to the financing announcement, BevCanna was trending higher and was building momentum. We believe that BevCanna is an opportunity to be aware of following the recent developments and will keep an eye on how the story evolves from here.

If you are interested in learning more about BevCanna Enterprises, please send an email to support@technical420.com with the subject ‘BevCanna Enterprises’ to be added to our distribution list.

Share Share - Facebook Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Source: https://technical420.com/cannabis-article/will-bevcanna-be-able-to-compete-long-term-with-the-likes-of-hexo-corp-and-canopy-growth/

Continue Reading

CBD

Hemptown USA Has Built A World Class Platform To Capitalize On The Booming Hemp Industry

In early 2021, we expect Hemptown USA to complete a go-public transaction and this is an opportunity that our readers should be aware of. We have been covering Hemptown since 2018 and are impressed with how the story has evolved during this time. In early 2017, Hemptown started to cultivate feminized hemp and is considered […]

The post Hemptown USA Has Built A World Class Platform To Capitalize On The Booming Hemp Industry appeared first on Technical420.

Republished by Plato

Published

on

In early 2021, we expect Hemptown USA to complete a go-public transaction and this is an opportunity that our readers should be aware of. We have been covering Hemptown since 2018 and are impressed with how the story has evolved during this time.

In early 2017, Hemptown started to cultivate feminized hemp and is considered to be a leading player in the cannabigerol (CBG) market. When we first met with Hemptown’s management team, the company was one of the few businesses to be focused on CBG and we are favorable on this focus.

Hemptown’s management team has a proven track record of success and is comprised of executives that previously worked at Fortune 500 companies (Intel and Kelloggs). We are favorable on how the management team has been able to make Hemptown standout in what has become a saturated market.

Positioned to Capitalize on the Current Market Environment

One of the reasons we are favorable on the opportunity is related to the infrastructure that has been put in place. Currently, Hemptown’s state-of-the-art FDA registered and cGMP certified facility is operating at 30% capacity and we expect this percentage to increase in 2021. Many of the company’s competitors are running out of capital and we have seen several CBD and CBG companies file for bankruptcy.

Last year, Hemptown raised $24 million through a series of private placements and has been cutting costs to conserve capital. This has left the business in a strong position to execute and we expect the company to record strong revenue growth as it ramps up capacity.

Another reason we are excited about Hemptown is related to how the business has evolved. The company has launched a line of hemp cigarettes that do not contain any nicotine and are made with CBD and CBG that is from its Oregon farm.

We have considered the hemp cigarette vertical to be an attractive market and are favorable on how Hemptown has differentiated its product line from what is currently available on the market. The products include a proprietary terpene infused filter that is available in a variety of flavors and we are favorable on this aspect of the story.

In a report from Cowen and Company, the US hemp industry is expected to be a $16 billion market by 2025. The passing of the 2018 US Farm Bill was a major catalyst for the cannabinoid market as it opened the door for an era of CBD commoditization. Following the passing of the bill, major retailers like Walgreens and CVS have entered the industry.

The surge of interest in the CBD market led to an even larger increase in the amount of production that companies had in place. This put substantial pressure on the price of CBD and high-profile operators like GenCanna (backed by Mitch McConnell) were forced to file for bankruptcy.

By being focused on multiple cannabinoids and by conserving cash, Hemptown has been able to survive the current market environment. We expect this aspect of the story to play an important role in how the business continues to grow and believe that Hemptown  is an operator to be aware of.

We believe that the next phase of growth for the market will be related to a surge in interest in cannabinoids like CBG, cannabichromene (CBC) and cannabidivarin (CBDV). We believe that Hemptown is positioned to be a beneficiary of this growth and will monitor how the story continues to evolve.

Executing on a Multi-Faceted Growth Strategy

Last year, Hemptown acquired Kirkman which is an established brand that has been in business for more than 70 years. Kirkman operates out of a facility that is FDA licensed and cGMP certified. When the acquisition was reported, we became increasingly excited about the opportunity and believe that Kirkland has played a key role how Hemptown has launched products.

By using state-of-the-art equipment for precision dosing, Hemptown has been able to create a diverse product line that includes tinctures, capsules, creams, topicals, gums, and edibles. The focus on being vertically integrated could increase margins by up to 20x and we are bullish on the impact that the facility has had on the economics of the business.

On top of selling its own product line, Hemptown offers white label products and we are favorable on the structure of the business. These products use premium cannabinoids and are fully traceable from seed-to-bottle. Hemptown’s white label platform is a full service offering that includes branding, fulfillment, and marketing services.

By operating a business model that has diversified revenue streams, Hemtown has been able to protect itself from decreasing CBD prices. The business model is based on margins and this is a key metric to be focused on. The strategy allows Hemptown to monetize inventory in multiple channels that are based on the demand and margins.

The saturation of the CBD market has substantially raised the cost of the end-consumer. Hemptown’s ability to sell to businesses and to consumers has protected margins while also being able to scale revenue. We believe that the strategy will allow Hemptown to efficiently monetize inventory and will monitor how the management is able to execute on this.

Focused on the International Opportunity

Another major potential growth driver for Hemptown is the expansion into the European Union (EU). Hemptown is pursuing a FSA license in the United Kingdom for its CBD and CBG products as well as bulk ingredients. The opportunity in the EU is massive and this is a market that we have been bullish on for several years.

Currently, Hemptown is in advanced discussions to partner with an established European supply chain that will provide it with the opportunity to move over 1,000 kilograms of CBD per month. We are favorable on the potential revenue that is associated with the relationship and will monitor how the company is able to capitalize on the EU market.

A Private Opportunity to be Aware of

Hemptown has attractive growth prospects and plans to make additional acquisitions to scale the business. The management has used a series of organic and inorganic growth initiatives to bring the business to where it is today.

We are favorable on the types of acquisitions that Hemptown has made and expect an additional acquisition to immediately prove to be accretive. We have faith in the management team’s ability to identify a business that would be complementary to the existing assets in place and are bullish on the potential impact it would have.

In early 2021, Hemptown plans to go public and this is an opportunity that we are closely following. If you are interested in learning more about Hemptown, please send an email to support@technical420.com with the subject “Hemptown” to be added to our distribution list.

Share Share - Facebook Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Source: https://technical420.com/cannabis-article/hemptown-usa-has-built-a-world-class-platform-to-capitalize-on-the-booming-hemp-industry/

Continue Reading

Uncategorized

Aurora Cannabis Obtains Receipt for Final Base Shelf Prospectus Reiterates Fiscal Q1 Guidance

Aurora Cannabis Inc. (the ” Company ” or ” Aurora “) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced it has filed and been receipted on a final short form base shelf prospectus (the “Shelf Prospectus”) with securities regulators in each of the provinces of Canada , except […]

The post Aurora Cannabis Obtains Receipt for Final Base Shelf Prospectus Reiterates Fiscal Q1 Guidance appeared first on Technical420.

Republished by Plato

Published

on

Aurora Cannabis Inc. (the ” Company ” or ” Aurora “) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced it has filed and been receipted on a final short form base shelf prospectus (the “Shelf Prospectus”) with securities regulators in each of the provinces of Canada , except Quebec , and a corresponding shelf registration statement on Form F–10 (the “Registration Statement”) with the United States Securities and Exchange Commission (the “SEC”).

Aurora Cannabis Inc. Logo (CNW Group/Aurora Cannabis Inc.)

The filing of the shelf prospectus is expected to provide financial flexibility to execute against previously stated business objectives. The Company expects to be in full compliance with all financial covenants as at September 30, 2020 under our amended and restated credit facility. Aurora’s relationship with the lending syndicate remains strong and there are no new obligations to repay any portion of the credit facility until its stated maturity date.

Following the divestiture of non-core subsidiaries during fiscal 2020, net revenue for the three months ended September 30, 2020 are expected to be comprised almost entirely of cannabis net revenue and expected to be at the high end of our previously announced $60 million to $64 million range, compared to $67.5 millionin Q4 2020. The Company also expects adjusted gross margin before fair value adjustments on cannabis net revenue to be at the high end of our previously announced 46%-50% range.

SG&A costs (including R&D) for the three months ended September 30, 2020 are expected to be in the low $40 million range after excluding certain one-time contract and employee termination costs.  Aurora continues to expect to achieve positive adjusted EBITDA in the second quarter of fiscal 2021.

About Aurora

Aurora is a global leader in the cannabis industry serving both the medical and consumer markets. Headquartered in Edmonton, Alberta , Aurora is a pioneer in global cannabis dedicated to helping people improve their lives. The Company’s brand portfolio includes Aurora, Aurora Drift, San Rafael ’71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, and Reliva CBD. Providing customers with innovative, high-quality cannabis products, Aurora’s brands continue to break through as industry leaders in the medical, performance, wellness and recreational markets wherever they are launched. For more information, please visit our website atwww.auroramj.com .

Aurora’s Common Shares trade on the TSX and NYSE under the symbol “ACB”, and is a constituent of the S&P/TSX Composite Index.

Forward Looking Statements

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (” forward-looking statements “). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements made in this news release include statements regarding: the Company’s goals of achieving positive Adjusted EBITDA and positive free cash flow. These forward-looking statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions, estimates and assumptions of management in light of management’s experience and perception of historical trends, current conditions and expected developments at the date the statements are made, such as current and future market conditions, the ability to maintain SG&A costs in line with current expectations, the ability to achieve high margin revenues in the Canadian consumer market, the current and future regulatory environment and future approvals and permits. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements, including the risks associated with: entering the U.S. market, the ability to realize the anticipated benefits associated with the acquisition of Reliva, achievement of Aurora’s business transformation plan, general business and economic conditions, changes in laws and regulations, product demand, changes in prices of required commodities, competition, the effects of and responses to the COVID-19 pandemic and other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual information form dated September 24, 2020 (the ” AIF “) and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com and filed with and available on the SEC’s website at www.edgar.gov . The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

The Company uses financial measures regarding itself, such as Adjusted EBITDA, that do not have standardized meaning under the International Financial Reporting Standards (” IFRS “) and may not be comparable to similar measures presented by other entities (” non-IFRS measures “). Further information relating to non-IFRS measures, is set out in the Company’s management discussion and analysis for the three and twelve months ended June 30, 2020 and 2019 under the heading “Cautionary Statement Regarding Non-GAAP Performance Measures” and the “Revenue” section for reconciliation to the IFRS equivalent.

Cision

View original content to download multimedia: http://www.prnewswire.com/news-releases/aurora-cannabis-obtains-receipt-for-final-base-shelf-prospectus-reiterates-fiscal-q1-guidance-301163790.html

SOURCE Aurora Cannabis Inc.

Source: https://technical420.com/cannabis-article/aurora-cannabis-obtains-receipt-for-final-base-shelf-prospectus-reiterates-fiscal-q1-guidance/

Continue Reading
CBD4 days ago

The New Italian Cannabis Contradiction

Heartland4 days ago

Bought Haven St. 150 peace tea. Looking for a review before I brew myself a cup

CBD2 days ago

Will Europe THC Limit Increase to 0.3%?

News4 days ago

Sugarbud Announces Supply Agreement with British Columbia Liquor Distribution Branch

Heartland4 days ago

Who Is Newly Lobbying On Cannabis?

Heartland4 days ago

Dosage recommendation and does it make anyone else feel groggy all day?

Heartland4 days ago

Vaping CBD flower doesn’t really do anything. Can you vape hash? Is my flower just too weak?

Heartland4 days ago

CBD vs CBN: What’s The Actual Difference?

Heartland5 days ago

Terp Town

News4 days ago

FluroTech Announces Filing of Patent Applications With Respect to Its Proprietary Diagnostic Test Method and Pandemic Defense Platform

News4 days ago

Rubicon Organics Establishes Route to Market for Cannabis 2.0 Products

Heartland4 days ago

CBD flower and hair testing?

Heartland4 days ago

What cbd cartridge brand is the best?

Heartland4 days ago

CBG for Crohn’s

Heartland3 days ago

Accountants from Coast to Coast Meet to Discuss Cannabis Issues

Material5 days ago

Kinetic modeling of the leaching of LiCoO2 with phosphoric acid

Heartland5 days ago

Global Cannabidiol Oil (CBD Oil) Market Data Analysis 2020-2026: Whistler, CBD American …

Heartland4 days ago

Canada’s Stubborn Black-Market Cannabis Problem

Heartland4 days ago

Cannabis Tycoon Curaleaf expected to monetize loads after Connecticut Legalizes

News4 days ago

Canada House Wellness Group Enters into Distribution Agreement for Cannabis 2.0 Products

News4 days ago

Canntab to Launch in Australia and Participate in Australia’s Largest Cannabis Research Study

Heartland4 days ago

MMJ Recs Medical Marijuana Cards And Your Privacy: Are MMJ Cards Confidential?

Heartland4 days ago

Exclusive: Colorado’s Governor Jared Polis Talks Legal Cannabis

Heartland4 days ago

CBD Hemp Oil Market Research Report Covers – Product Types, Applications, Market Share …

Heartland4 days ago

Is this site legit, or no?

News3 days ago

EBV Elektronik adds NanoXplore to its linecard

Material5 days ago

Study of HVOF-sprayed hydroxyapatite/titania graded coatings under in-vitro conditions

Material5 days ago

Experimental investigation on partition controllable induction heating-hot stamping process of high-strength boron alloyed steel plates with designable temperature patterns

Material5 days ago

Promising applicable heterometallic Al2O3/PbO2 nanoparticles in shielding properties

Heartland5 days ago

American Shaman Coupon Code 2020

Trending

A Cloud Nine Capital Entity Copyright © 2020 – All Rights Reserved Proudly Made in America